Patients with Crohn disease and the CC genotype may have be less likely to develop anti-adalimumab antibodes and therefore may have an increased response to adalimumab therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to adalimumab.